A 246C10 formulation with 3.0 mol% total PEG lipid, including 2.5 mol% mannose-PEG lipid, shifted Cre-mRNA expression toward LSECs. The remaining base lipids were 246C10/DOPE/cholesterol = 26.5/20/50.5 mol%, with 0.5 mol% non-targeted PEG lipid.
0.5 mg/kg mCre IV in LSL-tdTomato mice; n=5; tissue at 2 days · Main Results, Figs.6B and 7sales@dcchemicals.com
246C10
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| 246C10 | 26.5 | Ionizable lipid |
| DOPE | 20 | Helper phospholipid |
| Cholesterol | 52 | Sterol |
| C16-PEG2000 ceramide | 1.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation calculator unavailable. The full molar composition is reported, but the exact C16-PEG2000 ceramide product and average molecular weight are not mapped. The page therefore does not calculate component weights. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported6.75246C10 mRNA-LNPMain Results: Formulation of LNPs; cited Fig.S3C
Literature-reported80% hepatocytes, 40% LSECs and 10% Kupffer cells tdTomato-positive246C10 mCre-LNP; 0.5 mg/kg IV; n=5 · 2 daysMain Results and Fig.4C
Literature-reportedHighest liver luciferase expression among 244C10, 245C10 and 246C10 formulations0.1 mg/kg mFLuc IV in C57BL/6 mice · 3 hMain Results and Fig.3
Literature-reportedApproximately 400-fold increase in luciferase expression after ApoE preincubation246C10 mFLuc-LNP with ApoE3; anti-LDLR reduced expressionMain Results and Fig.2C-D
PEG-content series reported for 246C10 mCre-LNPs
| PEG lipid | Mean diameter | PDI | Encapsulation efficiency |
|---|---|---|---|
| 1.0 mol% | 97 ± 17 nm | 0.064 | 88.3 ± 7% |
| 1.5 mol% | 68 ± 15 nm | 0.127 | 90.1 ± 5% |
| 3.0 mol% | 58 ± 8 nm | 0.196 | 80.1 ± 8% |
Kim et al. 2021 main Fig.5A-B. PEG-lipid changes were offset by cholesterol.
Mannose-PEG LSEC-targeted variant
| Condition | Hepatocytes | LSECs | Kupffer cells |
|---|---|---|---|
| 3.0 mol% total PEG, no mannose | about 70% | about 13% | about 5% |
| 3.0 mol% total PEG, including 2.5 mol% mannose-PEG | 15% | 70% | 15% |
Kim et al. 2021 main Fig.7C; values in the no-mannose row are approximate readings from the plotted bars, whereas the mannose row is also stated in the text.
Additional reported findings
For siRNA experiments, the article used 246C10/DSPC/cholesterol/PEG lipid = 42.5/13/41.5/3 mol% for the 3% PEG condition; 2.5 mol% mannose-PEG was incorporated for LSEC targeting. The ionizable lipid:siRNA mass ratio was 7.5:1.
siFVII 0.2 mg/kg or siFVIII 0.5 mg/kg IV · Main Methods: In vivo gene silencing; Fig.8Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetKim M, Jeong M, Hur S, et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Science Advances. 2021;7:eabf4398. DOI: 10.1126/sciadv.abf4398
The hepatocyte and LSEC results use distinct 246C10 formulations. Mannose-dependent targeting is identified separately and is not a property claim for neat 246C10.
The hepatocyte and LSEC results use distinct 246C10 formulations. Mannose-dependent targeting is identified separately and is not a property claim for neat 246C10.